Funding breakthrough therapies: A systematic review and recommendation

E. Hanna, M. Toumi, C. Dussart, B. Borissov, O. Dabbous, K. Badora and P. Auquier

Health Policy, 2018, vol. 122, issue 3, 217-229

Abstract: Advanced therapy medicinal products (ATMPs) are innovative therapies likely associated with high prices. Payers need guidance to create a balance between ensuring patient access to breakthrough therapies and maintaining the financial sustainability of the healthcare system.

Keywords: Health policy; Healthcare financing; Drug costs; Innovative therapies (search for similar items in EconPapers)
Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (7)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851017303378
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:122:y:2018:i:3:p:217-229

DOI: 10.1016/j.healthpol.2017.11.012

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().